Therapeutic Peptide

TB-500 (Thymosin Beta-4)

Wound-healing peptide with strong animal data but minimal human clinical evidence.

Thymosin β4/actin polymerizationVEGF angiogenesisMMP matrix remodelingHIF-1α hypoxia response

41 C

Evidence Score

ⓘ For informational purposes only — not medical advice.

Score Breakdown

Overview

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino acid peptide involved in cell migration, wound healing, and tissue repair. Tβ4 has been studied in clinical trials for cardiac repair and corneal wound healing, though TB-500 itself (a partial sequence) has not undergone formal human trials.

Mechanism of Action

Thymosin beta-4 sequesters G-actin, regulating actin polymerization and cytoskeletal dynamics critical for cell migration and wound healing. It promotes angiogenesis via VEGF upregulation, modulates inflammatory cell recruitment, and activates matrix metalloproteinases (MMPs) for tissue remodeling.

Evidence Base

The parent peptide Tβ4 has been studied in Phase I/II clinical trials for cardiac repair (RegeneRx Biopharmaceuticals) and dry eye/corneal wound healing. TB-500, a synthetic fragment, has extensive veterinary use (equine) but limited formal human clinical data. Most human use data comes from anecdotal biohacking reports.

Gene Pathway Detail

Tβ4 modulates actin-dependent gene expression programs: VEGF and angiopoietin upregulation for angiogenesis, MMP2/MMP9 activation for extracellular matrix remodeling, and HIF-1α stabilization under hypoxic conditions. Biomeme could monitor these wound-healing gene signatures to assess molecular response.

mRNA Monitoring Insight

The wound-healing gene targets (VEGF, MMPs, HIF-1α) are well-characterized and monitorable via transcriptomics. TB-500 users could benefit from mRNA monitoring to determine whether the peptide is activating the expected tissue repair pathways, particularly in injury recovery contexts.

Safety Considerations

Parent peptide Tβ4 showed acceptable safety in limited clinical trials. TB-500 as a synthetic fragment has no formal human safety data. Widely used in equine veterinary medicine. Concerns include potential effects on tumor angiogenesis (VEGF upregulation). Not FDA-approved.

FAQ

What is the difference between TB-500 and thymosin beta-4?

TB-500 is a synthetic fragment of the larger thymosin beta-4 protein. While Tβ4 has been in clinical trials, TB-500 specifically has not. The relationship is similar to using a fragment vs. the whole molecule.

Quick Facts

Category: Therapeutic Peptide
Score: 41/100 (C)
Gene Pathways: 4 characterized

Sources

[1] Thymosin β4 and Wound Healing — Ann NY Acad Sci 2010

Compare Others

Monitor Your Peptide Response.

Biomeme's transcriptomic platform tracks molecular pathway engagement so you know if your therapy is working.